Zimbabwe has declined a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years over the United States' demand for sensitive biological samples.
This rejection came to light after a government memo dated December was leaked, revealing that President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesperson has since clarified that the United States was requesting health data for research and commercial gain while refused to share the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate process of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated over $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for more talks to find a agreement suitable to all parties so the nation's critical HIV programme can be sustained.
Wider Background
This rejection comes after a comparable case in neighbouring Kenya, where a court suspended a similar health funding agreement after concerns were raised about the security of citizens' health data.
After returning to office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking government-to-government deals to enhance openness and responsibility.
Based on statements, 16 African countries have to date agreed to similar health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to surrender its genetic material and health information for a long time, with no equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that could be developed from that shared data," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery without any assurance that the end products would be accessible to our people should a future disease outbreak emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining frameworks already established via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to deal with potential pandemics.
"This framework is designed to ensure that when a nation provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," he added.
"We encourage further discussions with our US partners on how subsequent collaboration could be arranged in a way that honours the sovereignty and interests of both nations."
Medical Community Response
A leading public health body stated it recognised the government's concerns, but urged that negotiations should continue considering much of the country's Aids initiatives depended on external financing.
"In cases where technical issues arise, such as those relating to data governance or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," it commented.
The situation emphasises the ongoing challenges between receiving much-needed international aid and safeguarding local interests in an ever more data-driven world.